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Abstract
Background: Evidence on the role of plasma exchange for treating recurrent post-transplant focal segmental
glomerulosclerosis (FSGS) comes largely from individual cases and uncontrolled series. We conducted a systematic
review and meta-analysis to estimate the remission rate after treatment with plasma exchange, and to determine if
remission varied with patient or treatment characteristics.
Methods: We searched MEDLINE, EMBASE, Science Citation Index Expanded, and the Conference Proceedings
Citation Index (Science and BIOSIS) for studies of patients with post-transplant recurrent FSGS who were treated
with plasma exchange after recurrence (1950–2012). Of 678 studies screened, 77 met our inclusion criteria: 34 case
reports (45 patients) and 43 case series (378 patients). We extracted patient-level data from each study and used
random-effects models to calculate remission, defined as proteinuria <3.5 g/day (partial) or <0.5 g/day (complete).
Results: The overall remission rate in 423 patients with outcome data was 71 % (95 % CI: 66 % to 75 %). In 235
patients with data on age, remission was similar for adults and children: 69.1 % (95 % CI: 59.6 % to 77.2 %) and 70.
2 % (95 % CI: 61.1 % to 77.9 %). Males were more likely to achieve remission (OR = 2.85; 95 % CI: 1.44 to 5.62) and
patients treated within 2 weeks of recurrence showed a trend towards higher likelihood of remission (OR = 2.16;
95 % CI: 0.93 to 5.01). Proteinuria >7 g/day at recurrence was inversely associated with remission (OR = 0.43; 95 %
CI: 0.19 to 0.97). Age and type of kidney transplant (living vs. deceased) did not associate with remission.
Conclusion: In this systematic review of patients with recurrent post-transplant FSGS, 71 % of patients achieved full
or partial remission after treatment with plasma exchange; however, extensive missing data and lack of a control
group limit any conclusions on causality.
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Background
Focal segmental glomerulosclerosis (FSGS) is the most
common acquired cause of kidney failure in children
(after hereditary causes), and accounts for nearly 40 % of
cases of nephrotic syndrome in adults [1, 2]. FSGS is a
clinical-pathological syndrome characterized by scarred
glomeruli, excessive protein excretion, and injured epi-
thelial podocytes. The primary cause is unknown in ap-
proximately 80 % of cases [2] and available treatments
have limited effectiveness. Even with treatment, 30–60 %
of patients progress to kidney failure within 5–10 years
and among those who receive a kidney transplant, severe
proteinuria recurs in 30–55 % of patients, often within
hours or days of grafting [3–7].
Recent studies suggest that primary FSGS may be
caused by plasma-borne factors that increase glomerular
permeability to albumin [3]. Treatment with plasma ex-
change became a logical step when several subtypes of
FSGS were found to recur in allograft-transplanted
kidneys, and with the discovery of potential pathological
circulating factors [7–10]. Plasma exchange replaces the
patient's blood plasma with a donor plasma product, re-
moving potential pathological factors from the patient’s
circulation, and has proved effective for treating acute
autoimmune disorders such as Guillain-Barre syndrome
and chronic conditions such as myasthenia gravis [11, 12].
While current guidelines support the use of plasma ex-
change for recurrent post-transplant FSGS, evidence on
treatment efficacy comes largely from case reports and
uncontrolled case series [3, 13]. We conducted a system-
atic review of all relevant studies of patients with post-
transplant recurrent FSGS (both adults and children) who
were treated with plasma exchange after recurrence. We
extracted patient-level data from these studies, and esti-
mated the rate of remission after treatment (defined as
proteinuria <3.5 g/day (partial) or <0.5 g/day (complete)),
and examined if remission varied with patient or treat-
ment characteristics.
Methods
Following the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) and Meta-Analysis
of Observational Studies in Epidemiology (MOOSE)
guidelines [14, 15], we performed a systematic review of
English-language articles using MEDLINE and PreMed-
line (OVID, 1966 to December 2012), EMBASE (1979 to
December 2012), Science Citation Index Expanded (1945
to December 2012), Conference Proceedings Citation
Index-Science (1990 to December 2012), BIOSIS Previews
(1955 to December 2012). Additional studies were identi-
fied through reviewing reference lists of retrieved studies.
A detailed search strategy is provided in Appendix I. The
study is exempt from ethics approval because we synthe-
sized data from previous published studies.
Study eligibility criteria were determined a priori. We
included all study designs of patients identified as having
recurrent post-renal transplant focal glomerulosclerosis
(FSGS) who were treated with plasma exchange at the
time of recurrence. Studies with no data on post-
treatment remission (defined below) were excluded. No
randomized controlled trials were identified in our
search. While some studies contained a comparison
group of patients with recurrent post-transplant FSGS
who did not receive plasma exchange, these comparison
groups largely comprised historical controls treated in
the decade prior to the cases. Data from these controls
were not included since these patients would have
lacked access to the same supportive treatment as cases
(leading to biased comparisons favoring plasma ex-
change). We defined a study as a case report if it de-
scribed one or two patients with recurrent FSGS who
were treated with plasma exchange. A study was defined
as a case series if it described three or more patients
with recurrent FSGS who were treated with plasma ex-
change (followed prospectively or retrospectively; the
largest sample size was 23).
The primary outcome in our study, remission after
treatment with plasma exchange, was defined as protein-
uria <0.5 g/day (complete remission) or proteinuria
between 0.5 − 3.5 g/day (partial remission). To be con-
servative, if data on protein was not available, but the
patient was reported as having achieved remission in the
primary study, we coded the patient as achieving partial
rather than complete remission. In the final analysis, pa-
tients who achieved complete or partial remission were
defined as responders and those who did not achieve re-
mission were defined as non-responders.
Data extraction
A data extraction form was prepared and piloted to de-
termine if changes were required before extracting data
from the full review. Two review authors (AK and RA)
independently extracted patient-level data from included
articles using pre-defined criteria and compared data to
achieve maximum reliability. Any disagreements were
reviewed and resolved by the authors.
Information was extracted on study and patient char-
acteristics, and on treatment details and outcomes.
Study characteristics included year of publication, coun-
try, study design, number of participants, and median
follow-up time. Patient characteristics included age, sex,
type of kidney transplant (living or deceased), level of
proteinuria at time of FSGS recurrence, biopsy testing,
time to recurrence, and time from recurrence to treat-
ment with plasma exchange. Treatment details included
the number of plasma exchange sessions, the number of
treatments, and the use of rituximab or steroids. Data
on patient outcomes at the end of follow-up included
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proteinuria, estimated glomerular filtration rate (eGFR),
progression to end-stage renal disease (ESRD), and the
time from transplant to ESRD.
Availability of Data and Materials: All the data sup-
porting the conclusions of this article are contained
within the manuscript. The individual patient-level data-
set was not made publically available due to containing
potentially identifying patient data; however, the data
may be made available from the authors upon request.
Analysis
Where possible, we collected individual-level data from
each study; however, missing data was >50 % for many
patient characteristics. Restricting the sample to only
those patients with complete data on prognostic vari-
ables would have excluded 70 % of the available sample,
possibly introducing selection and reporting biases. For
this reason, we present all available data, specifying the
amount of missing data for each variable (summarized in
Table 1 and in the text of the results). We used random-
effects models to estimate remission, which incorporates
study-specific random effects in addition to patient-specific
effects. We report the remission rate in the overall sample
and in sub-groups stratified by study design and age.
Characteristics of responders (those who achieved full
or partial remission) and non-responders were first sum-
marized using simple descriptive statistics. Percentages
were calculated based on valid denominators (i.e. de-
nominators exclude patients with missing data on the
characteristic of interest). Continuous data are summa-
rized using medians and interquartile ranges (IQR: 25th
percentile, 75th percentile). We used then generalized
estimating equations (adjusted for within-study cluster-
ing) to examine associations between remission and sev-
eral prognostic variables: age (<18 years and ≥18 years),
sex, type of kidney transplant (living vs. deceased), me-
dian proteinuria at recurrence (<7 g/day vs. ≥7 mg/d),
delayed treatment start (≤2 weeks vs. >2 weeks), and
treatment with rituximab. Odds ratios (OR) and 95 %
confidence intervals (95 % CI) are reported to describe
the statistical uncertainty of effect estimates [16]. All
data were analyzed using SAS 9.3 (SAS Institute Inc.,
Cary, NC, USA.).
Results
Study and patient characteristics
Of 678 citations identified in our search, 77 met our in-
clusion criteria (Fig. 1; references provided in Additional
file 1): 34 were case reports (45 patients) and 43 were
case series [378 patients]. Of 77 studies, 58 (76 %) were
full-text publications (229 patients) and 18 (24 %) were
abstracts (124 patients). Studies were conducted in 21
countries between 1985 and 2012. The median follow-
up time was 19 months (IQR 9, 56).
Characteristics of 423 patients with recurrent post-
transplant FSGS are summarized in Table 1. Raw data
are presented along with the percentage of missing data
for each characteristic. The median time to FSGS recur-
rence was 4 days (IQR 1, 18) (reported for 135 patients).
Median age at recurrence was 17 years (IQR 12, 33) (re-
ported for 235); 51 % were younger than 18 years (119/
235) and 59 % were male (126/212). Median proteinuria
at recurrence was 7 g/day (IQR 5, 12) (reported for 148).
The median time from recurrence to treatment with
plasma exchange was 1 day (IQR 0, 3); however, 12 %
(28/230) did not receive plasma exchange until >2 weeks
after recurrence. The total number of plasma exchange
sessions ranged from 1 to 200 with a median of 12 ses-
sions (IQR 10, 20). In addition to treatment with plasma
exchange, 10 % received rituximab (41/404) and 99 % re-
ceived steroids (341/344).
Remission from proteinuria after treatment with plasma
exchange
As shown in Table 1, 198 of 423 patients (46.8 %)
achieved complete remission after treatment with
plasma exchange, and 119/423 (28.1 %) achieved partial
remission. In a random-effects model that accounted for
patient- and study-specific random effects, the overall
remission rate was 71.0 % (95 % CI: 66.2 % to 75.4 %).
The remission rate in case-series studies was 72.5 %
(95 % CI: 67.4 % to 77.1 %) compared with 63.4 % in case
reports (95 % CI: 50.3 % to 74.8 %). In a restricted sample
of 235 patient with data on age, remission was similar for
adults and children: 69.1 % (95 % CI: 59.6 % to 77.2 %)
and 70.2 % (95 % CI: 61.1 % to 77.9 %), respectively.
A descriptive comparison of responders (those who
achieved full or partial remission) and non-responders is
shown in Table 2. Responders appeared to have a shorter
time to recurrence (3 days vs. 7 days) and lower protein-
uria at recurrence (7 g/day vs. 9 g/day); however, data on
protein was missing for 65 % of patients. The median
time to plasma exchange treatment was 1 day in both
groups; however, delayed treatment start (>2 weeks) ap-
peared to be more common among non-responders
(21 % vs. 9 %), and 19 % of non-responders had not re-
ceived plasma exchange within one month of recurrence,
compared with only 6 % of responders. Most other
variables were similar between groups, including age
(median 17 years), type of kidney transplant (deceased
donor: 64 %), and the median number of plasma
exchange sessions received (12 sessions). Finally, 9 % of
responders received rituximab compared with 14 % of
non-responders. Of the 41 patients who received rituximab,
29 (70.7 %) achieved remission, 7 responded to rituximab
but not plasma exchange, and 7 did not respond to either
plasma exchange or rituximab. After a median follow-up of
19 months (IQR 9, 56), median proteinuria was 0.1 g/day
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among responders and 4 g/day among non-responders,
and the median eGFR was 60 ml/min/1.73 m2 (IQR 37, 84)
and 15 ml/min/1.73 m2 (15, 40), respectively; 11 % of re-
sponders developed end-stage kidney disease compared
with 57 % of non-responders.
The results of the statistical analysis were consistent
with the descriptive analysis. In univariable regression
models that accounted for within-study clustering
(Table 3), males were nearly three times as likely to
achieve remission as females (OR 2.85; 95 % CI: 1.44 to
5.62), and patients who received plasma exchange within
two weeks of recurrence were twice as likely to achieve
remission as patients whose treatment initiation was de-
layed (OR 2.16; 95 % CI: 0.93 to 5.01), although the
latter effect estimate did not reach statistical signifi-
cance. Patients with proteinuria >7 g/day at recurrence
were less likely to achieve remission (OR 0.43; 95 % CI:
0.19 to 0.97). Age, type of kidney transplant, and treat-
ment with rituximab were not statistically associated
with remission. Effect sizes remained similar when we
restricted the sample to 110 patients with complete data
on age, gender, and time to treatment with plasma ex-
change, although confidence intervals became wider and
only gender remained statistically significant.
Discussion
We conducted a systematic review of 77 studies of pa-
tients with post-transplant FSGS who were treated with
Table 1 Characteristics and outcomes of patients treated with plasma exchange after primary post-renal transplant focal segmental
glomerulosclerosis (1950–2012)
Median or n (% of available data) Data not reported n (% of 423)
Characteristics at time of recurrence
Age at time of treatment (years), median (IQR) 17 (12,33) 188 (44 %)
< 18 years, n (%) 119/235 (50.6 %)
Gender, n (%) 211 (50 %)
Male 126/212 (59.4 %)
Female 86/212 (40.6 %)
Time to recurrence (days), median (IQR) 4 (1,18) 131 (31 %)
Proteinuria (g/day), median (IQR) 7 (5,12) 275 (65 %)
Biopsy conducted, n (%) 211/266 (79.3 %) 157 (37 %)
Kidney transplant type, n (%) 248 (59 %)
Living donor 62/175 (35.4 %)
Deceased donor 113/175 (64.6 %)
Treatment characteristics
Time from recurrence to start of plasma exchange (days), median (IQR) 1 (0,3) 193 (46 %)
Delayed treatment start, n (%) 193 (46 %)
More than two weeks 28/230 (12.2 %)
More than one month 22/230 (9.6 %)
Total number of plasma exchange sessions, median (IQR) 12 (10,20) 191 (45 %)
Total weeks of plasma exchange treatment, median (IQR) 12 (4,28) 309 (73 %)
Received rituximab 41/404 (4.7 %) 19 (4 %)
Received steroids 341/344 (99.1 %) 79 (19 %)
Post-treatment outcomes
Remission, n (%) 317/423 (74.0 %) 0
Complete remission (proteinuria <0.5 g/day) 198/423 (46.8 %)
Partial remission (proteinuria: 0.5–3.5 g/day)a 119/423 (28.1 %)
eGFR at follow up (ml/min/1.73 m2), median (IQR) 44 (25,74) 288 (68 %)
Proteinuria at follow-up (g/day), median (IQR) 0.2 (0,2) 259 (61 %)
End-stage renal disease, n (%) 83/381 (21.8 %) 42 (10 %)
Time to ESRD after transplant (years), median (IQR) 0.9 (0.3,2.0) 383 (91 %)
Abbreviations: eGFR estimated glomerular filtration rate, ESRD end-stage renal disease, IQR inter-quartile range
aIf protein data were not reported in the primary study, but the patient was reported as having achieved remission, we coded the patient as a partial remission
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plasma exchange at the time of recurrence. Overall,
71 % of patients achieved complete or partial remission
from proteinuria after treatment with plasma exchange
(95 % CI: 66 % to 75 %). Males were more likely to
achieve remission than females, and patients who re-
ceived plasma exchange within two weeks of recurrence
appeared more likely to achieve remission than patients
whose treatment initiation was delayed, although the lat-
ter did not reach statistical significance (the 95 % confi-
dence interval spanned 0.9 to 5.0). Patients with higher
proteinuria at recurrence (>7 g/day) were less likely to
achieve remission. Age and type of kidney transplant
(living vs. deceased) were not associated with remission.
While several narrative reviews have examined the role
of plasma exchange for recurrent post-transplant FSGS
[3, 6, 7, 17, 18], our study is the first systematic review
of this literature. We identified 34 case reports and 43
case series (76 % were full-text publications and 24 %
were abstracts). Although patient-level data was missing
for many prognostic variables including age and sex, we
were able to extract individual-level data on remission
for 423 patients. Overall 71 % of patients with recurrent
post-transplant FSGS achieved complete or partial




















incomplete data or 
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Fig. 1 Flow diagram of included studies (references for 77 included
studies and 38 excluded studies are provided in Additional file 1)
Table 2 Remission after treatment with plasma exchange for





Age at time of treatment (years),
median (IQR)
17 (13,32) 17 (11,38)
< 18 years, n (%) 89 (50.6 %) 30 (50.8 %)
Male, n (%) 106 (65.8 %) 20 (39.2 %)
Pre-treatment proteinuria (g/day),
median (IQR)
7 (5,12) 9 (6,15)
Biopsy conducted at time of
recurrence, n (%)
157 (77.3 %) 54 (85.7 %)
Time to recurrence (days), median (IQR) 3 (1,14) 7 (1,60)
Kidney transplant type, n (%)
Living donor transplant 47 (35.1 %) 15 (36.6 %)
Deceased donor transplant 87 (64.9 %) 26 (63.4 %)
Treatment characteristics
Time from recurrence to start of
plasma exchange (days), median (IQR)
1 (0,2) 1 (0,7)
Delayed treatment start, n (%)
More than two weeks 15 (9.0 %) 13 (20.6 %)
More than one month 10 (6.0 %) 12 (19.1 %)
Total number of plasma exchange
sessions, median (IQR)
12 (10,20) 12 (9,20)
Received rituximab 27 (8.9 %) 14 (14.0 %)
Received steroids 250 (99.2 %) 86 (98.9 %)
Post-treatment outcomes
eGFR at follow up (ml/min/1.73 m2),
median (IQR)
60 (37,84) 15 (15,40)
Proteinuria at follow-up (g/day),
median (IQR)
0.1 (0,0.5) 4 (1,6)
End-stage renal disease (ESRD), n (%) 31 (10.7 %) 52 (57.1 %)
Time to ESRD after transplant (years),
median (IQR)
1.4 (0.3,2.0) 0.8 (0.3,2.0)
Abbreviations: eGFR estimated glomerular filtration rate, ESRD end-stage renal
disease, IQR inter-quartile range (25th percentile, 75th percentile)
aComplete or partial remission: Full remission was defined as proteinuria <0.5 g/day;
partial remission was defined as proteinuria between 0.5 and 3.5 g/day. If
protein data were not reported in the primary study, but the patient was
reported as having achieved remission, we coded the patient as a
partial remission
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remission from proteinuria after treatment with plasma
exchange. This estimate is consistent with rates de-
scribed in narrative reviews (60 % to 73 %), and appears
favorable when compared to historical controls (i.e. pa-
tients with recurrent post-transplant FSGS not treated
with plasma exchange), where reported remission rates
are less than 30 %; however, most historical controls
would have lacked access to modern supportive therapy
and immunosuppressive treatment [19, 20].
In a descriptive comparison of responders (those who
achieved remission) and non-responders, we noted that re-
sponders appeared to have a shorter time to FSGS recur-
rence than non-responders (3 days vs. 7 days), and lower
levels of proteinuria at recurrence (7 g/day vs. 9 g/day).
While this may reflect differences in disease phenotype,
progression, or severity, it is also possible that responders
were monitored more closely after transplantation with the
result that recurrent FSGS was detected earlier and treated
more quickly. In regression analysis, patients who received
plasma exchange within two weeks of recurrence appeared
more likely to achieve remission than patients whose treat-
ment initiation was delayed. Although there is uncertainty
about the size of this effect (the 95 % CI spanned 0.9 to 5.0;
n = 230), these data suggest a beneficial effect of prompt
treatment with plasma exchange (i.e. a harmful effect seems
unlikely). However, the observational nature of the data
limits our ability to make any causal inferences about the
efficacy of plasma exchange independent of other concomi-
tant or supportive therapies.
Proteinuria may herald recurrent FSGS even if an early
biopsy does not show glomerular abnormalities [17].
KDIGO guidelines on proteinuria screening for post-
transplant primary FSGS recommend daily testing for
one week, weekly testing for four weeks, and every three
months thereafter; however, this schedule could result in
delayed detection and treatment among those who re-
lapse more than seven days after transplantation (who
may not then receive treatment until >14 days after re-
currence, when it may be too late). In some cases,
delayed treatment may result from confusion about re-
current patients mislabeled as suffering from prior min-
imal lesion nephropathy. However, the variability in the
literature suggests that early observation and interven-
tion strategies were not a practice standard, and current
guidelines may need to extend the period of initial pro-
teinuria testing.
In our study, males were nearly three times more likely
to achieve remission than females. At present, it is diffi-
cult to speculate on this marked gender variability in re-
sponse to plasma exchange therapy; however, other
studies have noted an increased incidence of recurrent
FSGS in females compared with males [6, 21]. Of note,
we saw similar remission rates for recipients of kidneys
from living vs. deceased donors, which may be encour-
aging given that other studies have noted an increased
risk of FSGS recurrence among recipients of kidneys
from living vs. deceased donors [12, 22].
Our findings should be interpreted with caution given
the many limitations of these data. All studies in our re-
view were observational with no concurrent comparison
groups. Missing data was greater than 50 % for many pa-
tient characteristics and prognostic variables, and eligi-
bility criteria were not always reported, limiting the
assessment of selection bias and external validity. Fur-
ther, treatment protocols were not standardized across
patients or studies. While all patients in this review re-
ceived plasma exchange therapy for post-transplant re-
current FSGS, many studies did not report the type of
replacement fluid used (i.e. 5 % serum albumin solution
vs. fresh frozen plasma). The time between recurrence
and treatment varied considerably as did the number of
plasma exchange sessions received. As well, immunosup-
pression treatment, pre-transplant prophylactic plasma
exchange, follow-up time, and outcome assessment var-
ied widely across patients and studies.
Estimating the overall effect of these biases is difficult.
While our estimate of remission may be inflated by se-
lection bias and publication bias, it may also be attenu-
ated by the wide variation in treatment protocols across
studies. For example, in one study that used a standard-
ized protocol to treat 10 consecutive patients with recur-
rent FSGS, nine patients achieved complete remission
and one achieved partial remission when plasma ex-
change was initiated within ten days of recurrence and
administered three times per week for three weeks (ta-
pered to once per month after five months) along with
high-dose oral steroids and intravenous cyclosporine.
Unfortunately, a parallel-group randomized controlled
trial may not be feasible given the rareness of this condi-
tion (<1 %), and also, it is questionable whether suffi-
cient equipoise for such a trial exists.
Future research should examine and refine the treat-
ment protocol (timing, dosage, prescription of 5 % serum
Table 3 Associations with remission: Individual-level meta-
regression of available data
OR (95 % CI)
Adults vs. children (235 patients; 55 studies) 1.09 (0.55 to 2.16)
Males vs. females (212 patients; 54 studies) 2.85 (1.44 to 5.62)
Proteinuria at recurrence (≥7 g/day vs. <7 g/day)
(148 patients; 40 studies)
0.43 (0.19 to 0.97)
Received rituximab (404 patients; 72 studies) 0.60 (0.21 to 1.75)
Transplant type (living vs. deceased) (423 patients;
46 studies)
1.00 (0.43 to 2.30)
Plasma exchange within 2 weeks of FSGS
recurrence (230 patients; 54 studies)
2.16 (0.93 to 5.01)
Odds ratios (OR) and 95 % confidence intervals estimated using generalized
linear estimating equations to account for within-study clustering
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albumin solution vs. fresh frozen plasma, duration of
plasma exchange treatment after remission); long-term
patient outcomes (in some cases FSGS may recur months
or years after transplant); [8] the efficacy of pre-transplant
plasma exchange for preventing recurrence; supportive
therapy; and develop new hypothesis-driven therapies—a
difficult endeavor given that the cause of primary FSGS
remains unknown. While many studies support a plasma-
borne pathophysiology, a specific mechanism has yet to
be identified despite intensive research, and we still lack a
reliable diagnostic test [3, 17].
Conclusions
In this systematic review of patients with recurrent post-
transplant FSGS, 71 % of patients achieved full or partial
remission from proteinuria after treatment with plasma
exchange. Patients treated within two weeks of recur-
rence appeared to have a higher likelihood of remission
from proteinuria, although this finding must be inter-
preted with caution given the observational nature of
the data. Nonetheless, it seems prudent to support care-
ful observation in the post-transplant period (daily pro-
teinuria testing for at least 14 days) for patients with a
prior diagnosis of FSGS or minimal change nephrotic
syndrome; if proteinuria is detected, immediate initiation
of plasma exchange therapy may be a potentially useful
therapeutic option.
Additional file
Additional file 1: Citations of Included and Excluded Studies. (PDF 121 kb)
Appendix I
Search Strategy
A systematic literature search was performed for all rele-
vant English and non-English language articles using
MEDLINE and PreMedline (OVID, 1966 to December
2012), EMBASE (1979 to December 2012), Science
Citation Index Expanded (1945 to December 2012),
Conference Proceedings Citation Index- Science (1990
to December 2012), BIOSIS Previews (1955 to December
2012). Additional studies were identified by reviewing
reference lists of retrieved studies and by contacting
clinical experts. Search terms included plasmapheresis,
aphaeresis, plasma exchange, focal segmental glomerulo-
sclerosis, FSGS, focal glomerulosclerosis, recurrent FSGS
Abbreviations
CI, confidence intervals; eGFR, estimated glomerular filtration rate; ESRD, end stage
renal disease; FSGS, focal segmental glomerulosclerosis; IQR, interquartile range;
KDIGO, kidney disease improving global outcomes; MOOSE, meta-analysis of
observational studies in epidemiology; OR, odds ratio; PRISMA, preferred reporting
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